Difference between revisions of "MRI-based Biomarkers for Characterization of Amyotrophic Lateral Sclerosis"
(Created page with "The overarching goal of the proposed study is to quantify spinal cerebrospinal fluid (CSF) dynamics and geometry as a novel biomarker for ALS using magnetic resonance imaging...") |
|||
| Line 1: | Line 1: | ||
| − | The | + | ==Team== |
| + | *[[Bryn Martin]] | ||
| + | *[[Gregory Carter]] | ||
| + | *[[Douglas Weeks]] | ||
| + | *[[Brian Petersen]] | ||
| + | |||
| + | ==Problem== | ||
| + | Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurological disorder that affects approximately 3.9 in 100,000 people within the United States. This devastating disease leads to degeneration of motor neurons and certain death. Research shows that 90 to 95 percent of ALS cases appear to occur at random, with no clearly associated biomarkers. Only 5-10 percent of ALS cases are inherited. Current neuroimaging techniques are only partly capable of characterizing ALS into distinct clinical phenotypes. Early stages of ALS can be similar to a wide variety of more treatable disorders. Thus, there is an urgent need to identify ALS biomarkers that allow earlier diagnosis and to recognize disease subtypes. The goal of the proposed study is to, for the first time, quantify spinal cerebrospinal fluid (CSF) dynamics and geometry in participants with ALS using advanced engineering analysis of non-invasive magnetic resonance imaging (MRI) measurements. | ||
Revision as of 22:11, 9 May 2016
Team
Problem
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurological disorder that affects approximately 3.9 in 100,000 people within the United States. This devastating disease leads to degeneration of motor neurons and certain death. Research shows that 90 to 95 percent of ALS cases appear to occur at random, with no clearly associated biomarkers. Only 5-10 percent of ALS cases are inherited. Current neuroimaging techniques are only partly capable of characterizing ALS into distinct clinical phenotypes. Early stages of ALS can be similar to a wide variety of more treatable disorders. Thus, there is an urgent need to identify ALS biomarkers that allow earlier diagnosis and to recognize disease subtypes. The goal of the proposed study is to, for the first time, quantify spinal cerebrospinal fluid (CSF) dynamics and geometry in participants with ALS using advanced engineering analysis of non-invasive magnetic resonance imaging (MRI) measurements.
